
Moderna, Inc. (NASDAQ:MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.
mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza